2022
The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects.
Jones JD, Mumtaz M, Vadhan NP, Martinez S, Pramanik S, Manubay J, Mogali S, Perez F, Castillo F, Kranzler HR, Comer SD. The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects. Behavioural Pharmacology 2022, 33: 255-265. PMID: 35438671, PMCID: PMC9149033, DOI: 10.1097/FBP.0000000000000671.Peer-Reviewed Original Research
2021
Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users
Mogali S, Askalsky P, Madera G, Jones JD, Comer SD. Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users. Pharmacology Biochemistry And Behavior 2021, 209: 173241. PMID: 34298029, PMCID: PMC8429209, DOI: 10.1016/j.pbb.2021.173241.Peer-Reviewed Original ResearchConceptsAnalgesic effectRecreational opioid usersReceptor-selective agonistOpioid usersPreclinical studiesAbuse liabilityNew York State Psychiatric InstituteRelease of cytokinesPositive subjective effectsTetracycline antibiotic minocyclineYears of ageDouble-blind outpatient studyPositive subjective responsesGlial activationAcute administrationCertain medicationsHuman research volunteersOutpatient studyGlial cellsNon-treatment seekingSame dosesRewarding effectsOxycodoneDrug AdministrationMinocycline
2020
Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.
Brandt L, Jones JD, Martinez S, Manubay JM, Mogali S, Ramey T, Levin FR, Comer SD. Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder. Drug And Alcohol Dependence 2020, 208: 107859. PMID: 31980285, PMCID: PMC7063580, DOI: 10.1016/j.drugalcdep.2020.107859.Peer-Reviewed Original Research
2019
Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone.
Jones JD, Mumtaz M, Manubay JM, Mogali S, Sherwin E, Martinez S, Comer SD. Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone. Pharmacology, Biochemistry, And Behavior 2019, 186: 172778. PMID: 31493434, PMCID: PMC6801039, DOI: 10.1016/j.pbb.2019.172778.Peer-Reviewed Original Research
2018
The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety.
Jones JD, Bisaga A, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Madera G, Doernberg M, Comer SD. The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. Journal Of Psychoactive Drugs 2018, 50: 390-401. PMID: 30204554, PMCID: PMC6487639, DOI: 10.1080/02791072.2018.1508789.Peer-Reviewed Original Research
2017
Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential.
Jones JD, Comer SD, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Martinez S, Mumtaz M, Bisaga A. Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. Pharmacology, Biochemistry, And Behavior 2017, 163: 90-100. PMID: 29020601, PMCID: PMC5959043, DOI: 10.1016/j.pbb.2017.10.002.Peer-Reviewed Original ResearchAbuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.
Jones JD, Manubay JM, Mogali S, Metz VE, Madera G, Martinez S, Mumtaz M, Comer SD. Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. Drug And Alcohol Dependence 2017, 179: 362-369. PMID: 28844013, DOI: 10.1016/j.drugalcdep.2017.06.033.Peer-Reviewed Original ResearchEffects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence
Metz VE, Jones JD, Manubay J, Sullivan MA, Mogali S, Segoshi A, Madera G, Johnson KW, Comer SD. Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 2017, 42: 1825-1832. PMID: 28393896, PMCID: PMC5520790, DOI: 10.1038/npp.2017.70.Peer-Reviewed Original ResearchConceptsEffect of ibudilastVisual analog scaleAnalgesic effectOpioid dependenceEffects of oxycodoneGlial cell activationOpioid use disorderTreatment of asthmaDrug Effects QuestionnaireRecent preclinical studiesCold pressor testNonselective phosphodiesterase inhibitorMaintenance doseOxycodone administrationAnalog scaleWithdrawal symptomsDrug likingHeroin cravingPressor testMale volunteersPreclinical studiesIbudilastPatient detoxificationUse disordersOxycodone
2015
The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users
Jones JD, Sullivan MA, Manubay JM, Mogali S, Metz VE, Ciccocioppo R, Comer SD. The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users. Physiology & Behavior 2015, 159: 33-39. PMID: 26455893, PMCID: PMC5444321, DOI: 10.1016/j.physbeh.2015.10.006.Peer-Reviewed Original ResearchConceptsEffect of pioglitazoneAbuse liabilityOpioid usersOpioid agonist effectsGood drug effectEffects of opioidsAbility of pioglitazoneActivation of PPARγPrescription opioid abusersDose-dependent increaseAddictive-like responsePositive subjective responsesMaintenance doseDaily dosesOpioid abusersOpioid receptorsPain perceptionReceptor agonistAgonist effectsDrug effectsOxycodonePioglitazoneRespiratory rateOpioidsCognitive effectsAbuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.
Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, Comer SD. Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. Addiction Biology 2015, 20: 784-98. PMID: 25060839, PMCID: PMC4305506, DOI: 10.1111/adb.12163.Peer-Reviewed Original ResearchBaseline characteristics of patients predicting suitability for rapid naltrexone induction.
Mogali S, Khan NA, Drill ES, Pavlicova M, Sullivan MA, Nunes E, Bisaga A. Baseline characteristics of patients predicting suitability for rapid naltrexone induction. The American Journal On Addictions / American Academy Of Psychiatrists In Alcoholism And Addictions 2015, 24: 258-264. PMID: 25907815, PMCID: PMC4496800, DOI: 10.1111/ajad.12180.Peer-Reviewed Original Research
2013
Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use
Gudin JA, Mogali S, Jones JD, Comer SD. Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use. Postgraduate Medicine 2013, 125: 115-130. PMID: 23933900, PMCID: PMC4057040, DOI: 10.3810/pgm.2013.07.2684.Peer-Reviewed Original ResearchConceptsChronic opioid therapyUrine drug testingOpioid analgesicsChronic painOpioid therapyAberrant drug-related behaviorsAlcohol useOpioid-related abuseAdjustment of treatmentDrug testingTherapeutic drug monitoringDrug-related behaviorsCombination opioidsAdverse eventsNonfatal overdoseSedative agentsTreatment complianceClinical changesPatient outcomesBZD treatmentAberrant behaviorPractice guidelinesHigh riskClose monitoringPainEffects of Acute Oral Naltrexone on the Subjective and Physiological Effects of Oral D-Amphetamine and Smoked Cocaine in Cocaine Abusers
Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA, Jones JD, Vosburg SK, Cooper ZD, Roux P, Sullivan MA, Manubay JM, Rubin E, Pines A, Berkower EL, Haney M, Foltin RW. Effects of Acute Oral Naltrexone on the Subjective and Physiological Effects of Oral D-Amphetamine and Smoked Cocaine in Cocaine Abusers. Neuropsychopharmacology 2013, 38: 2427-2438. PMID: 23736314, PMCID: PMC3799062, DOI: 10.1038/npp.2013.143.Peer-Reviewed Original ResearchBuprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone
Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain 2013, 154: 1442-1448. PMID: 23707283, PMCID: PMC3770461, DOI: 10.1016/j.pain.2013.05.004.Peer-Reviewed Original ResearchConceptsBUP/NXWithdrawal symptomsChronic painDrug choiceOral oxycodoneMaintenance doseBuprenorphine/naloxone maintenanceOpioid withdrawal symptomsReduction of painPromising therapeutic optionMore withdrawal symptomsLogistic regression analysisSelf-administer oxycodoneMann-Whitney testOxycodone doseOxycodone dosesMaintenance dosesBuprenorphine/Prescription opioidsMore painOxycodone useTherapeutic optionsClinical painInpatient studyOpioid abuse
2012
Polydrug abuse: A review of opioid and benzodiazepine combination use
Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug And Alcohol Dependence 2012, 125: 8-18. PMID: 22857878, PMCID: PMC3454351, DOI: 10.1016/j.drugalcdep.2012.07.004.Peer-Reviewed Original Research
2001
Ab initio analysis of lithium dimethylaminoborohydride.
Mogali S, Darville K, Pratt LM. Ab initio analysis of lithium dimethylaminoborohydride. The Journal Of Organic Chemistry 2001, 66: 2368-73. PMID: 11281777, DOI: 10.1021/jo001600j.Peer-Reviewed Original Research